Australian Small-Cap Investigator | The ‘Body Hackers’ An...

  Australian Small-Cap Investigator | The ‘Body Hackers’

An announcement slated for July 2015 could send this stock NINE times higher

This is an extract from PPP news letter.
The 'holy-grail' for any biotech company is product reimbursement.
This means the government will reimburse patients who choose treatment with this company's stem cell products.
If this happens revenues and profits could blow sky-high.
Right now, this firm is able to freely sell its products in the Australian market.
However at some point in July 2015, the company is due to learn if its products will be accepted onto the Australian Register of Therapeutic Goods (ARTG).
ARTG registration opens the door to most Asian markets including New Zealand, Singapore, Hong Kong and Malaysia — so it alone is a worthy goal.
Remember, these are PROVEN products already available on the Australian market today, backed by a long history of successful product trials.
You're not just looking at men and women in white coats testing things in a lab.
This is an established company pulling in millions of dollars each year.
This holds the company in good stead for an ARTG tick of approval.
If approval is granted you could see this company's stock price double within days, triple within weeks and potentially head towards 900% over the coming months.
Nice!!!